JAJoelma Maria de Araújo Andrade

Joelma Maria de Araújo Andrade

*This is an algorithmically generated author record based on publicly available information.

Joelma Maria de Araújo Andrade has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigating whether H5N1 is a risk to human populations in Brazil

    by Claudio Bruno Silva de Oliveira, Joelma Maria de Araújo Andrade, Shahina Akter, Maria Karolaynne da Silva, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira

  • Open Access

    Are atypical lymphocytes a new predictive factor in the development of COVID-19?

    by Claudio Bruno Silva de Oliveira, Joelma Maria de Araújo Andrade, Jonas Ivan Nobre Oliveira

  • Open Access

    Fighting COVID-19

    by D. M. O. Campos, C. B. S. Oliveira, J. M. A. Andrade, J. I. N. Oliveira

    The current COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and severe forms of respiratory infection. The lack of vaccines and antivirals prevents clinical strategies against the disease, creating an emerging need for the development of safe and effective treatments. Strategies for vaccine development include complete vaccines against viruses, subunits, and nucleic acids, but are still in their early stages. Studies carried out to date on possible SARS-CoV2 drug targets highlight glycoprotein S, Mpro (main protease or protease type 3C), and a member of the transmembrane serine protease II families (TMPRSS2). However, due to the pandemic state, priority is given to marketed drugs. These include chloroquine (CQ), hydroxychloroquine (HCQ), nitazoxanide, remdesivir, Lopinavir/ritonavir (LPV / r), in addition to treatment with convalescent plasma. But, therapeutic specific effects against SARS-CoV2 have not yet been verified. Most of the information obtained about treatment is based on preliminary and limited studies. We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.


  • Effect of toxoplasmic infection on the biodistribution of a brain radiopharmaceutical

    by João Cláudio da Costa Urbano, Ranny Beatriz de Carvalho Holanda Leite, Renan Leopoldo Pereira Castro, Clarice Maux Vianna da Silva, Joelma Maria de Araújo Andrade, Cláudio Bruno Silva de Oliveira, Vanessa Santos de Arruda Barbosa, Valter Ferreira de Andrade-Neto, Cecília Maria de Carvalho Xavier Holanda

    Purpose: This study evaluated if Toxoplasma gondii infection and the drug-associated infection modifies the brain radiopharmaceutical Ethylene Cystine Diethylester Dihydrochloride (99mTc-ECD) biodistribution in mice. Materials and methods: A total of 18 mice were divided into 3 groups. Control group (C) received distilled water and 99mTc-ECD; Infected group (I) received T. gondii strain and 99mTc-ECD; Infected and Treated group (IT), in addition to infection, received association of Pyrimethamine and Sulfadiazine and 99mTc-ECD. The T. gondii strain used in this study was TgCkRrRN3. Forty minutes after administration of the 99mTc-ECD, all animals were euthanized, and blood and brain samples were isolated. The counting of the radioactivity percentage per gram of tissue (%ATI/g) was calculated, and statistical analysis was performed by t-test, with a level of significance of p < .05. Results: There was a significant increase in %ATI/g between groups C and I on brain (0.35 ± 0.02 and 0.45 ± 0.04; p = .041) and on blood (0.80 ± 0.09 and 1.14 ± 0.31; p = .049). A significant decrease in %ATI/g occurred between groups C and IT on blood (0.80 ± 0.09 and 0.54 ± 0.08; p = .001) and on brain (0.35 ± 0.02 and 0.22 ± 0.04; p = .049). Conclusions: Combined therapy of anti-Toxoplasma drugs in infected mice reduced the uptake of 99mTc-ECD, probably due to its binding to plasma proteins.

  • Open Access

    THE INFLUENCE OF SALT INTAKE ON THE COURSE OF EXPERIMENTAL TOXOPLASMOSIS IN OUTBRED OR INBRED MOUSE STRAINS

    by Claudio Bruno Silva de Oliveira, Ywlliane Da Silva Rodrigues Meurer, Valeska Santana de Sena Pereira, Joelma Maria de Araújo Andrade, Juliete Tavares, Valter Ferreira de Andrade Neto

    Many environmental factors contribute to an effective immune response against Toxoplasma gondii (Tg) infection, among which diet is important in triggering the immune response of the host to infection. Emerging reports suggest that salt intake undermines the regulatory mechanisms mediated by innate and adaptive immune cells. Unfortunately, the impact of an Intermediate Salt Diet (ISD) on the pathogenesis and immune response to toxoplasmosis remains unclear. The purpose of this study was to evaluate the susceptibility profile to an ISD (NaCl 2%) of two mouse strains (outbred Swiss and inbred C57BL6) infected by the ME49 strain of Tg. Our data confirm an antagonistic susceptibility to oral Tg infection among the two mouse strains. Sodium intake induced the highest mortality in C57BL6 compared to Swiss mice in the infected groups. A simultaneous ISD with the infection did not induce significant differences in body weight in either mouse strains. Both mouse strains showed an antagonistic response to a sodium intake diet on the number of parasite brain cysts. An increased number of brain cysts in C57BL6 ISD-Tg animals were noted while Swiss ISD-Tg animals presented a decrease in the number of brain cysts compared to NSD-Tg (Normal Salt Diet) for both mouse strains. Furthermore, sodium intake caused a significant reduction in the specific humoral immune response against Tg in inbred C57BL6 mice. Thus, our data reveal that an ISD affects the humoral immune response in the murine model and influences the course of Tg infection.


  • An alternative nested-PCR assay for the detection of Toxoplasma gondii strains based on GRA7 gene sequences

    by Maria Eduarda S.M. Costa, Claudio Bruno S. Oliveira, Joelma Maria de A. Andrade, Thatiany A. Medeiros, Valter F. Andrade Neto, Daniel C.F. Lanza


  • Open Access

    Pathogenicity and phenotypic sulfadiazine resistance of Toxoplasma gondii isolates obtained from livestock in northeastern Brazil

    by Claudio Bs Oliveira, Ywlliane Sr Meurer, Joelma Ma Andrade, Maria Esm Costa, Milena MC Andrade, Letícia A Silva, Daniel Cf Lanza, Ricardo Wa Vítor, Valter F Andrade-Neto

    Toxoplasma gondii is the causative protozoan agent of toxoplasmosis, which is a common infection that is widely distributed worldwide. Studies revealed stronger clonal strains in North America and Europe and genetic diversity in South American strains. Our study aimed to differentiate the pathogenicity and sulfadiazine resistance of three T. gondii isolates obtained from livestock intended for human consumption. The cytopathic effects of the T. gondii isolates were evaluated. The pathogenicity was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using a CS3 marker and in a rodent model in vivo. Phenotypic sulfadiazine resistance was measured using a kinetic curve of drug activity in Swiss mice. IgM and IgG were measured by ELISA, and the dihydropteroate synthase (DHPS) gene sequence was analysed. The cytopathic effects and the PCR-RFLP profiles from chickens indicated a different infection source. The Ck3 isolate displayed more cytopathic effects in vitro than the Ck2 and ME49 strains. Additionally, the Ck2 isolate induced a differential humoral immune response compared to ME49. The Ck3 and Pg1 isolates, but not the Ck2 isolate, showed sulfadiazine resistance in the sensitivity assay. We did not find any DHPS gene polymorphisms in the mouse samples. These atypical pathogenicity and sulfadiazine resistance profiles were not previously reported and served as a warning to local health authorities.